Clinical Trial Update: Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI) [Phase 2]

View source ↗

Summary

Phase 2 trial update examining tacrolimus after rATG and infliximab induction immunosuppression for renal transplant rejection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplant Rejection

Drugs mentioned

• Infliximab (infliximab)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Prof. Dr. Petra Reinke | Conditions: Renal Transplant Rejection | Phase 2 | Status: COMPLETED